![Enhertu](https://pharmaphorum.com/wp-content/uploads/2020/12/Enhertu.jpg)
AZ, Daiichi challenge Roche with EU okay for earlier use of ...
AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive metastatic breast cancer, moving the drug up the treatment pathway.